On November 19, Menovo disclosed that it had received a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) for its venlafaxine hydrochloride API from the European Directorate for the Quality of Medicines & HealthCare (EDQM). Source: http://finance.eastmoney.com/a/202611193935180661.html
On November 19, Luye Pharma (02186) announced that China’s National Medical Products Administration had approved Ruoxinlin® (toludesvenlafaxine hydrochloride extended-release tablets), its in-house Class 1 innovative drug, for generalized anxiety disorder. This is the product’s second approved indication in China, following its initial approval for depression in November 2022. The company said the drug improves anxiety symptoms and supports patients’ overall condition and social functioning, with favorable overall safety and tolerability. The new indication broadens the product’s clinical use. Source: http://finance.eastmoney.com/a/202611193935196418.html
On November 19, Lianhuan Pharmaceutical announced that China’s National Medical Products Administration had approved its marketing application for bilastine API. Bilastine is a long-acting, nonsedating antihistamine that selectively antagonizes peripheral H1 receptors. It has no affinity for muscarinic receptors and low affinity for other receptors. Source: http://finance.eastmoney.com/a/202611193935255859.html
On November 19, Grand Pharma announced that China’s National Medical Products Administration had cleared its in-house nebulized candidate GPN01564 for a Phase I clinical study in respiratory syncytial virus (RSV). The company reported favorable drug development characteristics, safety and efficacy in preclinical studies. Source: http://finance.eastmoney.com/a/202611193935308279.html
On November 19, Tianjin Pharmaceutical (600488) disclosed that China’s National Medical Products Administration had approved its marketing application for dexamethasone active pharmaceutical ingredient (API). Dexamethasone has antiallergic, antipyretic and immunosuppressive properties and is used primarily for allergic and autoimmune inflammatory diseases. The article lists marketed Chinese dosage forms including single-ingredient dexamethasone tablets and combination products in eye drops, ophthalmic ointments, topical ointments and injections. Source: http://finance.eastmoney.com/a/202611193935031069.html
On November 19, The United Laboratories (03933) announced that China’s National Medical Products Administration had granted implicit clinical trial clearance for UBT48128 tablets, a Class 1 innovative drug developed by its wholly owned subsidiary, United Biotechnology in Zhuhai Hengqin. UBT48128 is an investigational small-molecule GLP-1 receptor agonist intended for once-daily oral use. It is designed to lower blood glucose and body weight as a potential treatment option for people with overweight or obesity. The candidate previously received US FDA clearance for clinical trials on August 11, 2026. Source: http://finance.eastmoney.com/a/202611203935753843.html
Drugdu.com expert’s respons When engaging in foreign trade of medical consumables, some suppliers may encounter such scenarios: overseas buyers only place a first order for a few hundred or a few thousand pieces of products, yet they require their own brand logo to be printed, the quantity per box adjusted, and even the packaging design and label language replaced. For manufacturing enterprises, such orders are often not easy to handle. The product quantity is small, but extra investment is required for packaging design, procurement of printing materials, production scheduling and document review. If calculated according to the standards for normal commercial orders, the customization cost may be relatively high; if the enterprise bears all the costs to win the customer, there is a concern that there will be no repeat orders afterwards. So why do some overseas buyers insist on customized packaging even with a small purchase volume? For suppliers, ...
Organiser:TECNOSALUD AREQUIPA Time:November 18 – 20, 2026 Address:Javier Prado Este 4200 Surco., Lima, Peru Exhibition hall:Jockey Plaza Product range: Diagnostic equipment and instruments: Diagnostic devices, diagnostic instruments First aid equipment: First aid devices Respiratory equipment: Respiratory devices Imaging equipment: Imaging devices Dialysis equipment: Dialysis devices Bandages: Bandages Gauze: Gauze Endoscopes: Endoscopes Staplers: Surgical staplers Dental diagnostic equipment: Dental diagnostic devices Dental handpieces: Dental handpieces Periodontal examination systems: Periodontal inspection systems Dental surgical equipment: Dental surgical devices Dental anesthesia equipment: Dental anesthesia devices Periodontal materials: Periodontal materials Pharmaceuticals: Pharmaceuticals Anesthetics: Anesthetic drugs Raw materials: Raw materials Intermediates: Pharmaceutical intermediates Biological preparations: Biological agents Chemicals: Chemicals Health products: Health products Dietary supplements: Healthcare supplements Laboratory instruments: Laboratory instruments Optical instruments: Optical instruments Image analysis and processing systems: Image analysis and processing systems Testing instruments: Testing devices Laboratory renovation and upgrading technologies: Laboratory renewal and transformation technologies Consumables: Medical consumables Software: Medical ...
Drugdu.com expert’s respons When enterprises plan to manufacture and sell Class II medical devices in China, they are usually required to obtain a Medical Device Registration Certificate first. However, many enterprises that are new to the registration process often have questions: which authority should they submit the application to? What documents need to be prepared? Do all products need to undergo clinical trials? And once they have the registration certificate, can they directly start production and sales? In accordance with the Regulations on the Supervision and Administration of Medical Devices and the Measures for the Administration of Medical Device Registration and Filing, medical devices in China are categorized into Class I, Class II and Class III based on their risk levels. Among them, Class I devices are subject to filing management, while Class II and Class III devices are subject to registration management. Domestic Class II medical devices are under the charge of ...
Organiser:MEDICA Time:November 16 – 19, 2026 Address:Ostfach 10 10 06, D-40001 Düsseldorf, Stockum Church Street 61, D-40474, Düsseldorf, Germany – D-40001 Exhibition hall:Düsseldorf Exhibition Center Product range: Medical Equipment: Medical electronic instruments, clinical laboratory analysis instruments, dental equipment and materials, hemodialysis equipment, respiratory equipment, hospital ward equipment, operating room equipment, emergency room equipment, hospital office equipment. Imaging and Diagnostics: Ultrasound instruments, X-ray equipment, medical optical instruments. Disposable Consumables: Disposable medical supplies, dressings and sanitary materials, surgical instruments. Medical Devices: Healthcare equipment, home healthcare products, physical therapy, orthopedic technology. Medical Peripherals: Information and communication technology, medical services and publications, IT systems and IT solutions. About MEDICA Düsseldorf: MEDICA Düsseldorf, Germany is the world’s largest and most authoritative exhibition for hospitals and medical equipment. With its irreplaceable scale and influence, it ranks first among global medical trade shows. Held annually in Düsseldorf, Germany, it showcases a full range of products ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.